Business Context and Reporting Period
This Form 8-K is filed by Organovo Holdings, Inc. (not Vivosim Labs, INC.) on January 16, 2025. The report addresses a critical regulatory event regarding the company's continued listing on The Nasdaq Capital Market under the symbol ONVO.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. The report focuses exclusively on regulatory compliance status.
Material Changes
- Delisting Notice: On January 16, 2025, Nasdaq notified the company that it failed to regain compliance with the minimum bid price requirement of $1.00 per share (Rule 5550(a)(2)) by the January 14, 2025 deadline.
- Ineligibility for Second Period: The company is not eligible for a second 180-day compliance period because it does not meet the requirements for initial listing on The Nasdaq Capital Market.
- Immediate Action: The company intends to request a hearing before a Hearings Panel to stay the delisting action.
Guidance, Outlook, and Risks
- Compliance Plan: Management intends to present a plan to the Hearings Panel, which may include conducting a reverse stock split to meet the bid price requirement.
- Timeline: If a hearing is granted, the Panel has discretion to extend the compliance period up to July 15, 2025.
- Risks: There is no assurance that the Panel will grant an extension, that the company will regain compliance, or that the stock will remain listed. The filing includes standard forward-looking statement disclaimers regarding these uncertainties.
Investor Verification Checklist
- Verify the current status of the hearing request with Nasdaq.
- Monitor the company's stock price to assess the likelihood of meeting the $1.00 bid price requirement.
- Review upcoming announcements regarding the potential implementation of a reverse stock split.
- Check for any subsequent filings detailing the outcome of the Hearings Panel decision.